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The search for melanoma biomarkers is crucial, as the incidence of melanoma continues to rise. We have previously demonstrated
that serum CEACAM1 (sCEACAM1) is secreted from melanoma cells and correlates with disease progression in metastatic
melanoma patients. Here, we have used a diﬀerent cohort of melanoma patients with regional or metastatic disease (N = 49),
treated with autologous vaccination. By monitoring sCEACAM1 in serum samples obtained prior to and after vaccination, we
show that sCEACAM1 correlates with disease state, overall survival, and S100B. The trend of change in sCEACAM1 following
vaccination(increase/decrease)inverselycorrelateswithoverallsurvival.DTHskintestisusedtoevaluatepatients’anti-melanoma
immune response and to predict response to vaccination. Importantly, sCEACAM1 had a stronger prognostic value than that of
DTH, and when sCEACAM1 decreased following treatment, this was the dominant predictor of increased survival. Collectively,
our results point out the relevance of sCEACAM1 in monitoring melanoma patients.
1.Introduction
Malignant melanoma is a main cancer-related cause of
death in people below 30. While its incidence continues
to rise more rapidly than that of any other malignancy,
until lately, therapy had shown only moderate success and
caused numerous adverse eﬀects [1–3]. A new hope for
melanoma patients has emerged now from the development
of a speciﬁc B-RAF inhibitor and the entry of immune
checkpoint modulators to the clinic. In spite of this progress,
the monitoring of melanoma patients still presents a clinical
challenge as it heavily relies on history taking, physical
examination, and wide imaging studies [4]. This, together
with the fact that melanoma can remain dormant for long
periods of time before relapsing [5], emphasizes the need
for valid melanoma biomarkers. Currently, the two most
widelyusedmelanomabiomarkersarelactatedehydrogenase
(LDH) and the calcium binding protein S100B [6–8]. Serum
levels of S100B or LDH correlate with poor outcome and
are associated with shorter disease-free and overall survival
[9, 10]. Several studies showed the prognostic value of S100B
and LDH in predicting successful therapeutic treatments for
malignant melanoma patients [11–16]. Unfortunately, how-
ever, serum S100B and LDH are not speciﬁc for melanoma.
Abnormal elevation of S100B accompanies liver and kidney
injuries as well as inﬂammatory and infectious diseases [17],
while elevated LDH is also observed in liver injury, cell
damage, hemolysis, and so forth [18–20].
CEACAM1(carcinoembryonicantigen-relatedcelladhe-
sion molecule 1) is a transmembrane multifunctional cell-
cell adhesion molecule, belonging to CEACAM, a subdi-
vision of the Ig Superfamily. Broadly expressed in human
epithelial, endothelial, and hematopoietic cells, it regu-
lates immune responses, neovascularization, and insulin
clearance (reviewed in [21, 22]). Membranal CEACAM1
(mCEACAM1) expression is downregulated in some types2 Clinical and Developmental Immunology
of cancer [23–26] and its reexpression by tumor cells inhibits
in vivo tumor growth [27, 28], leading to the original
deﬁnition of mCEACAM1 as a tumor suppressor. However,
in several cancers, including malignant melanoma and non-
small-cell lung cancer, mCEACAM1 is upregulated and
its expression highly correlates with tumor progression,
the development of metastasis, and poor survival [29–
31]. Immunohistochemical analysis on superﬁcial spreading
melanoma, dysplastic nevi and benign nevi, showed that
mCEACAM1 is stepwise elevated during the course of
malignant melanoma progression [32]. Patient monitoring
proved that its predictive value for metastasis formation
and poor survival is superior to that of tumor thickness
and independent of other factors, including ulceration,
tumor thickness, and mitotic rate [29]. Mechanistic evidence
regarding the role of mCEACAM1 in melanoma is scarce. In
vitro studies have demonstrated that mCEACAM1 promotes
melanoma cell migration and invasion [33]a sw e l la sp r o t e c -
tion from elimination by cytotoxic NK and T cells [34–36].
We have recently identiﬁed a soluble form of human CEA-
CAM1 (sCEACAM1), which is produced and secreted from
melanoma cells in a process that demands active protein
synthesis and intact intracellular vesicular transport [37].
Monitoringofmetastaticmelanomapatientsforserumlevels
of sCEACAM1 showed that patients with evidence of dis-
ease (WED) exhibit signiﬁcantly higher serum sCEACAM1
levels as compared to patients with no clinical evidence
of disease (NED) or with healthy volunteers. sCEACAM1
levels correlated with LDH, and most importantly, stratiﬁed
the metastatic patients into two prognostic groups with
diﬀerent survival rates [37]. These results exhibit the prog-
nostic value of sCEACAM1 for melanoma progression and
survival.
In this study, we monitored melanoma patients with
regional or metastatic disease, treated with autologous cell
vaccination. Melanoma is unique among human cancers
as it induces signiﬁcant numbers of anti-tumor reactive
lymphocytes during the natural course of tumor growth
[38]. Vaccination with modiﬁed autologous melanoma cells
given as a postsurgical adjuvant therapy is thought to elicit
this naturally occurring immune response and to prolong
disease-free period [39, 40]. Vaccination may be beneﬁcial
especially in selected patients who show successful anti-
melanoma immune response, as reﬂected by the delayed-
type-hypersensitivity (DTH) test (i.e., positive skin reac-
tion to subcutaneous injection of unmodiﬁed autologous
melanoma cells) [39, 40].
Here, we monitored 49 melanoma patients (AJCC stages
III-IV) treated with autologous tumor vaccination in the
years 1998–2010 and focused on sCEACAM1 evaluation.
We found that sCEACAM1 correlates with disease state
and is also likely to correlate with survival rate. Moreover,
the change in sCEACAM1 over time (increase or decrease)
correlated with overall survival and had a superior value over
DTH skin response. In addition, post-vaccination sCEA-
CAM1 correlated with S100B. These observations support
the prognostic value of sCECACM1 and its potential role in
monitoringofmelanomapatientswithregionalormetastatic
disease.
2. Patients andMethods
2.1. Patients. Patients with pathologically veriﬁed cutaneous
MM in AJCC stages III-IV in the years 1998–2010 were
included. Two patients with thick cutaneous melanomas
AJCCstageIIBwereincludedinthisseries,onacompassion-
ate basis. Clinical characteristics of participants are detailed
inTable 1.Therewereno exclusioncriteria.AllNEDpatients
were treatment-na¨ ıve (were not treated before vaccination).
WED patients were accrued on the condition that they
had progressed following ﬁrst-line treatment (DTIC, IL-2
or both). Patients’ evaluation was done by CT scan of the
whole body, performed within 28 days prior to treatment
initiation. All melanoma patients gave written informed
consent prior to their participation in this study. This study
was approved by the Institutional Review Board of Hadassah
Hebrew University Hospital, Jerusalem.
2.2. Vaccination. The protocol used for vaccine preparation
and delivery was as previously described [40]. Both NED
and WED patients were treated with the same protocol.
Brieﬂy, 10–25 × 106 autologous melanoma cells were sub-
cutaneously injected in each dose of vaccine. On treatment
day, the cells were thawed, washed, and irradiated to 170Gy.
Conjugation of melanoma cells with DNP (dinitrophenol)
was performed by the method of Miller and Claman [41].
Bacille Calmete Guerin (BCG) was used as an adjuvant and
mixed with tumor cells. DNP sensitization was induced by
applying 0.1mL of 2% DNP dissolved in acetone-corn oil
(Sigma Aldrich) topically to the inner aspect of the arm. The
ﬁrst two vaccine doses were preceded by cyclophosphamide,
300mg/m2, given as an immunomodulatory dose. The
vaccinewasinjectedinto3adjacentsitesontheupperarmor
thigh, avoiding limbs where lymph node dissection has been
previously performed. An overall of eight doses of vaccine
were administrated at intervals of 21–28 days.
2.3. Specimen Characteristics. Blood samples were obtained
from patients before the ﬁrst vaccine was administered
(usually up to 2 months after surgery), and following the 5th
or 8th vaccination, by venipuncture and standard handling
procedures. 15 milliliters of blood were collected in citrate-
containing tubes (BD Biosciences) and then centrifuged at
700g for 10 minutes in room temperature to obtain sera.
All serum samples were collected and divided into aliquots
and frozen in −80◦C until analysis. Anonymous samples
(marked only with ID number) were linked only to clinical-
pathological data.
2.4.CEACAM1andS100BEvaluationbyELISA. sCEACAM1
serum levels were measured by the Sandwich ELISA protocol
d e s c r i b e di n[ 37]. Soluble S100B in the serum was estimated
by ELISA according to the manufacturer’s instruction [42].
Half of the samples were analyzed in Hadassah Medical
Center and the others in Sheba Medical Center. The results
obtained from the two medical institutes showed some
diﬀerences, probably due to variability in sample handling,
freezing/thawing cycles, and batches of antibodies used. InClinical and Developmental Immunology 3
Table 1: Depiction of the clinical characteristics of 20 WED and 29 NED melanoma patients used in this study.
Total number of patients 49 (100%)
Age (years) at treatment Sex, Female 25 (51%)
<40 9 (18.4%)
41–60 16 (32.7%)
>61 24 (49%)
Stage at presentation Time from ﬁrst treatment to last follow up date
Stage II 2 0–12 months 12 (24.5%)
Stage III 32 13–24 months 13 (26.5%)
Stage IV 15 25–36 months 4 (8.2%)
>37 months 20 (40.8%)
Stage at treatment of NED patients (N = 29) Stage at treatment of WED patients (N = 20)
Stage II 2 (6.9%) Stage III (unresectable) 10 (50%)
Stage III (respectable) 22 (76%) Stage IV: M1a 1 (5%)
Stage IV: M1b 2 (6.9%) M1b 1 (5%)
M1c 3 (10.3%) M1c 8 (40%)
LDH values of NED patients LDH values of WED patients
Time point 0: Time point 0:
normal 87% (20/23) normal 78% (11/14)
above normal 13% (3/23) above normal 21% (3/14)
Time point 1: Time point 1:
normal 78% (18/23) normal 64% (7/11)
above normal 22% (5/23) above normal 36% (4/11)
Table 2: sCEACAM1 correlates with S100B. ELISA measurements
of posttreatment sCEACACM1 and S100B yielded values that
were divided relative to median levels into “low” and “high.” The
correlations between the two resulted “low” subgroups, as well
as between the two “high” subgroups, were tested and found to
be signiﬁcant (P = 0.02). Percentages in each cubical refer to
sCEACACM1 (ﬁrst row) or to S100B (second row).
Low S100B
N = 25
High S100B
N = 23
Low CEACAM1
N = 29
N = 19 N = 10
65.5% (19/29) 34.5% (10/29)
76% (19/25) 43.5% (10/23)
High CEACAM1
N = 19
N = 6 N = 13
31.6% (6/19) 68.4% (13/19)
24% (6/25) 56.5% (13/23)
order to compensate for these diﬀerences, the two medians
(one for each group of samples) were calculated, and each
sCEACAM1 value was divided by the median of its group
(Figures 1, 2 and Table 2). In this analysis, sCEACAM1
values which equal the median are represented by 1 and
values high/lower than median by >1o r<1 values. Similar
normalization was performed for S100B (Table 2). When
analyzing ΔsCEACAM1 values (post-vaccinations 5th or
8th minus pre-1st vaccination levels, Figures 3-4), absolute
rather than normalized sCEACAM1 values were used.
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Figure 1: sCEACAM1 in WED patients increases over time and
as compared with NED patients. sCEACAM1 was measured by
ELISA in serum samples of 29 NED (A, B) and 20 WED (C,D)
malignant melanoma patients, both before (time point 0) and
following treatment (time point 1). Vertical lines indicate medians.
2.5. DTH Evaluation. Skin testing to evaluate delayed type-
hypersensitivity to autologous melanoma cells was per-
formed by intradermal injection of 1–3 × 106 unmodiﬁed
m e l a n o m ac e l l si r r a d i a t e da tad o s eo f1 7 0 G y ,a sa l r e a d y
described in [40]. We arbitrarily chose the value of 10mm of4 Clinical and Developmental Immunology
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Figure 2: The correlations between sCEACAM1 and survival. The whole group of patients and NED exclusively or WED exclusively were
divided into two groups (“low”/“high”) according to pre-treatment sCEACAM1 median level, and the survival rate of each subgroup was
analyzed by Kaplan-Meier analysis. Group sizes were as follows: N = 24 (low) and N = 25 (high) in (a); N = 15 (low) and N = 14 (high) in
(b).
erythema to discriminate between negative DTH (<10mm)
and positive DTH (≥10mm).
2.6.StudyDesign. Thisstudywasretrospective.Nostratiﬁca-
tion or matching were used and patients (the great majority
of them from AJCC stages III and IV) were selected in a
random manner. Sample size (N = 49) matched previous
similar studies (reviewed in [43]) and was suﬃcient for
analysis of the results. Samples were obtained from June
1998 through October 2010. Median follow-up time was 23
months.
2.7. Statistical Analysis. The analysis was focused on the
impact of sCEACAM1 on disease progression and sur-
vival. Overall survival was estimated by the Kaplan-Meier’s
method.Signiﬁcance(P value)wascalculatedbyMantel-Cox
regression.
3. Results
3.1. Soluble CEACAM1 Correlates with Disease State. Our
study encompassed 49 melanoma patients, staged, based on
AJCC 2002, as AJCC II (N = 2), III (N = 32), and IV (N =
15), that were treated with autologous vaccination (Table 1).
The patients were categorized according to the clinical
manifestation of disease into patients with no evidence of
disease (NED; N = 29; 22/29 in AJCC III) and patients
with active disease (WED; N = 20, 10/20 in AJCC III and
10/20 in AJCC IV). Accordingly, most patients exhibited
normal LDH values (Table 1). It should be noted that
autologous vaccination is beneﬁcial for selected patients andClinical and Developmental Immunology 5
uncommonly yields objective tumor regressions [39, 40].
In our cohort of patients, it did not result in any tumor
regression (Table 1). Measurement of serum CEACAM1
(sCEACAM1) in blood samples over time (i.e., before as
compared to following vaccination; Figure 1, C as compared
to D), revealed a 20% elevation of sCEACAM1 in the WED
group and no elevation in the NED group (A as compared
to B). Comparison of WED to NED patients demonstrated
a 20% elevation in WED patients, both at basal time point
(Figure 1, mean sCEACAM1 = 0.93 in a as compared to
1.11 in C; P = 0.024) and following vaccination (Figure 1,
mean sCEACAM1 = 1.0 in B as compared to 1.19 in D;
P = 0.068). These results are in line with our previous
ﬁndings in a diﬀerent cohort of melanoma patients and
treatments, describing a signiﬁcant elevation in sCEACAM1
inWEDascomparedtoNEDpatientsandhealthyvolunteers
[37].
3.2. Soluble CEACAM1 Correlates with Survival in NED
Patients. We next categorized the whole group of patients
according to their basal (pre-treatment) sCEACAM1 values
into “high” and “low” subgroups (see “Methods”). Analysis
of overall survival rates using Kaplan-Meier plots revealed
an inverse correlation between sCEACAM1 and survival
(Figure 2). This correlation was evident though it did not
reach statistical signiﬁcance. While in the low-sCEACAM1
subgroup (Figure 2(a); black, N = 24), the mean overall
survival rate was 62 months, it was only 44 months for
high-sCEACAM1 patients (Figure 2(a);g r a y ,N = 25)
and 49 months for the whole population of patients. In
order to rule out the possibility that these results stem
from the fact that most low-sCEACAM1 patients (70.8%)
were NED (i.e., patients whose expected survival is higher),
the same analysis was performed for each of the patients
groups separately. As can be seen in Figure 2(b), NED
patients whose sCEACAM1 was low were likely to have
a higher overall survival rate (black, 80.8 months, N =
15) as compared to sCEACAM1high NED patients (Gray,
61 months, N = 14). In WED patients, pre-treatment
sCEACAM1 had no prognostic value on survival rate
(Figure 2(c)).
3.3. The Change in sCEACAM1 over Time Inversely Correlates
with Survival. In order to test the correlation between
sCEACAM1 and survival in the whole group, independently
of patients’ status as NED or WED, we calculated the change
in sCEACAM1 after treatment for each of the 49 patients
(ΔsCEACAM1). The sCEACAM1 levels before treatment
served as the point of reference. Patients were divided into
two groups according to the trend (“increased”/“decreased”)
of ΔsCEACAM1 and Kaplan-Meier analysis was performed
foreachofthegroups(Figure 3).Remarkably,the26patients
that exhibited a decrease in sCEACAM1 levels during
followup were characterized by a mean overall survival rate
of 63 months, whereas the 23 patients in which sCEACAM1
was increased had a mean survival rate of only 40 months
(P = 0.055). The trend of change of sCEACAM1 thus
positively correlated with survival.
All patients; P = 0.05 1
0.8
0.6
0.4
0.2
0
(months)
0 2 04 06 08 0 1 0 0 1 2 0
sCEACAM1
sCEACAM1
C
u
m
.
 
s
u
r
v
i
v
a
l
Figure 3: The change of sCEACAM1 following vaccination
inversely correlates with survival. The change in sCEACAM1
following treatment (post minus pre-vaccination) was calculated
and the patients (N = 49) were divided according to the trend of
sCEACAM1 change. Kaplan-Meier plots were used to describe the
survival rates of each subgroup of patients. Groups sizes were as
follows: N = 26 (decreased sCEACAM1) and N = 23 (increased
sCEACAM1).
3.4. The Correlation of ΔsCEACAM1 with Survival Is Stronger
thanThatofDTHTest. DTH(delayed-typehypersensitivity)
skin reactivity using unmodiﬁed autologous melanoma cells
is used to predict the ability of patients to develop an
immune response against his/her tumor and is attributed
to the vaccination procedure [39, 40]. Survival rate of the
patients was analyzed in DTH-negative and DTH-positive
groups,accordingtothetrendinΔsCEACAM1.Surprisingly,
the DTH-negative group, that is, patients that were not
expected to gain a survival beneﬁt from the vaccine (N =
24), could be categorized according to ΔsCEACAM1 into
two distinct prognostic groups (Figure 4(a)). Indeed, the 11
patients that exhibited a decrease in sCEACAM1 had a mean
overall survival rate of 63 months, as compared to only 29
months in the 13 patients in which sCEACAM1 levels were
increased (Figure 4, P = 0.03). In contrast, no signiﬁcant
diﬀerences were found between ΔsCEACAM1 subgroups in
DTH-positive patients (P = 0.58, Figure 4(b)). These results
indicate that CEACAM1 monitoring with ΔsCEACAM1 has
anaddedandcomplimentaryvaluetotheDTHresponsetest.
3.5. The Correlation Between sCEACAM1 and S100B. We
have previously demonstrated that sCEACAM1 signiﬁ-
cantly correlates with LDH serum levels in metastatic
melanoma patients [37]. Here, we analyzed the correlation
between sCEACAM1 and another known melanoma serum
biomarker, S100B. We could not observe a correlation
between the absolute values of these two factors (data not
shown). However, when categorizing values into high/low
subgroups, we found a signiﬁcant (P = 0.02) correlation
between post-vaccination S100B and sCEACAM1 (Table 2),
thatis,lowsCEACAM1wasmostlikelytobeaccompaniedby6 Clinical and Developmental Immunology
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Figure 4:MonitoringofsCEACAM1furtherstratiﬁesDTH-negativepatients intotwoprognosticallydistinctgroups.Theanalysisdescribed
in Figure 3 was performed exclusively for (a) DTH-negative patients (N = 24) and (b) DTH-positive patients (N = 23). Subgroups sizes
were N = 11 (DTH−)o rN = 15 (DTH+) for decreased sCEACAM1 and N = 13 (DTH−)o rN = 8( D T H +) for increased sCEACAM1.
low S100B in the same patient, and vice versa. To conclude,
sCEACAM1correlatedwithdiseasestateandwithS100Band
its dynamics over time highly correlated with overall survival
rates.
4. Discussion
In this retrospective study, we examined 49 melanoma
patients from advanced AJCC stages, before and following
autologous vaccination, for serum sCEACAM1 levels. We
found that sCEACAM1 increases over time in WED patients
and that their sCEACAM1 levels are higher as compared
to NED patients (Figure 1). This conﬁrms our previously
published results with a diﬀerent cohort of melanoma
patients and treatments [37]. As most NED and WED
patients are at AJCC Stages III and IV, respectively, this
result implies that sCEACAM1 could reﬂect disease burden.
Indeed, sCEACAM1 is synthesized and secreted from cul-
turedhumanmelanomacellsanditsconcentrationscorrelate
with the amount of seeded melanoma cells in vitro [37]
as well as with tumor mass in mice (unpublished data).
In addition, post-vaccination sCEACAM1 correlates with
S100B (Table 2), which sensitively reﬂects tumor mass [9].
Collectively, this data further fortiﬁes the possible value of
sCEACAM1 in monitoring disease burden.
Importantly, high sCEACAM1 levels are likely to corre-
late with poor overall survival (Figure 2) and signiﬁcantly
discriminated between patients who died and patients who
remained alive during follow-ups. However, to rule out
the possibility that these observations stem entirely from
the correlation of sCEACAM levels with disease burden
(stage and evidence of disease) we analyzed the trend of
sCEACAM1 change over time (post-vaccination minus pre-
vaccination) for each of the patients. Remarkably, “increased
sCEACAM1” patients had signiﬁcantly poor overall survival
rates as compared with “decreased sCEACAM1” patients,
both in the whole group of patients (Figure 3) and in NED
or WED patients subgroups. This indicates that monitoring
of serum sCEACAM1 in melanoma patients has a prognostic
predictive value. Furthermore, the majority of the patients
in this cohort exhibited normal values of serum LDH
(Table 1). This was not surprising, as the majority of the
patients were either with no evidence of disease (29/49
patients) or with Stage III (10/49 patients). Blood marker
levels were compared 6-7m in average after initiation of
treatment. None of the NED patients and most Stage
III patients exhibited clinically evident progression during
this period, which was supported by the normal LDH
values. In contrast, sCEACAM1 levels enabled predictive
stratiﬁcation of the patients (Figures 2 and 3). It is therefore
implied that in patients with normal LDH (mainly NED
and Stage III), sCEACAM1 might have superior predictive
value.
We have previously reported that autologous vaccina-
tion was associated with improved overall and disease-free
survival in AJCC stage III melanoma patients who attained
strong skin reactivity against their tumor cells [39, 40].
The decrease in sCEACAM1 in NED/Stage III patients
following vaccination is in line with this data. Moreover,
more “decreased sCEACAM1” patients were found among
DTH-positive patients (15/23 = 65%) as compared with
DTH-negative patients (11/24 = 46%), but this diﬀerence
did not reach statistical signiﬁcance, probably due to small
population size. Interestingly, monitoring of ΔsCEACAM1
further identiﬁed two distinct prognostic subgroups (P =
0.03) among the DTH-negative patients, but not in the
DTH-positive patients. It is implied that the change in
sCEACAM1 during vaccination can identify more subtle, yet
of prognostic importance, immune events that the crud skin
test is unable to show. Therefore, sCEACAM1 has an added
prognostic value to DTH test and both could be used in
adjunct to achieve superior patient stratiﬁcation.Clinical and Developmental Immunology 7
Overall, the current data suggest that the alterations in
serum sCEACAM1 levels in melanoma patients reﬂect dis-
ease activity and support its role as a reliable serum marker.
This prognostic value could be derived from the reﬂection
of disease burden by sCEACAM1, as described previously
[37]. However, serum sCEACAM1 may be more than a
biomarker and may also have a biological functional and
play an active role in facilitating melanoma aggressiveness.
The previous ﬁndings that sCEACAM1 is produced by active
protein synthesis in melanoma cells and that its production
does not result from protein cleavage [37] actually support
this idea. Membrane-bound CEACAM1 protects melanoma
cells from NK and T cells-mediated cytotoxicity and enable
them to avoid immune attack. Expressed and secreted
from melanoma cells but not from immune cells [37],
sCEACAM1 might act in a similar manner as a soluble ago-
nistic ligand, which activates membrane-bound CEACAM1
receptors on NK and T cells thereby inhibiting their eﬀec-
tor functions. sCEACAM1 may also agonistically enhance
other CEACAM1-mediated functions, such as angiogenesis.
Alternatively, it antagonize membrane-bound CEACAM1
to inhibit the adhesive interactions between lymphocytes
and activated endothelial cells, thus aﬀecting the rolling,
adhesion,andrecruitmentoflymphocytes.Thesehypotheses
remain to be proven in future investigations.
The mechanism of sCEACAM1 production is currently
unknown. It was shown in mice that removal of Exon 4
by alternative splicing generates a truncated protein due
to a stop codon created at the junction between Exon 3
and Exon 5 [44]. A similar sequence analysis of the human
CEACAM1 shows that the junction between Exons 3 and
5 creates a new stop codon, thus sCEACAM1 may be
formed as a result of speciﬁc alternative splicing. Revealing
the cues that induce sCEACAM1 expression/secretion, as
well as characterization of sCEACAM1 functional domains,
will help in deciphering whether the intriguing sCEACAM1
protein harbors biological functionality.
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